BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.
Presentation Details
Format: Corporate presentation
Date: Monday, February 26, 2024
Time: 2:00 PM ET
To learn more about the BIO CEO and Investor Conference please visit https://bcic.bio.org/.
About CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-430-7579
| Last Trade: | US$8.30 |
| Daily Change: | -0.12 -1.43 |
| Daily Volume: | 38,066 |
| Market Cap: | US$68.470M |
March 17, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
